©2024 Stanford Medicine
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer
Trial ID: NCT04809584
Purpose
The purpose of this research study is to see if patients' tumor can be identified by
18F-DCFPyL PET/MRI scan. The radioactive study agent, 18FDCFPyL, combined with PET/MRI scan
may be able to identify smaller tumors than the standard of care contrast-enhanced CT or MRI
scan.
Official Title
18F-DCFPyL PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-risk Prostate Cancer
Stanford Investigator(s)
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Eligibility
Inclusion Criteria:
1. Patient is older than 18-year-old
2. Biopsy proven prostate adenocarcinoma
3. Planned prostatectomy with lymph node dissection
4. Intermediate to high-risk disease (as determined by elevated Prostate-specific antigen
(PSA) [PSA>10], T-stage [T2b or greater], Gleason score [Gleason score > 6] or other
risk factors)
5. Able to provide written consent
6. Karnofsky performance status of ³50 (or Eastern Cooperative Oncology Group (ECOG)
/World Health Organization (WHO) equivalent)
Exclusion Criteria:
1. Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy including focal
ablation techniques (HiFu)
2. Androgen deprivation therapy or other neoadjuvant treatments prior to PET imaging
surgery
3. Metallic implants (contraindicated for MRI)
Intervention(s):
drug: F18-DCFPyL
drug: Gadolinium
procedure: Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Pranav Hedge
650-721-4080